Form 4: Pressure BioSciences Director Acquires Shares Through Interest Payment
SEC Form 4 Filing
Director Michael S Urdea acquired 14,429 shares of Pressure BioSciences Inc. common stock on September 27, 2024, through interest payment on convertible preferred stock.
Summary
- On September 27, 2024, Michael S Urdea, a director of Pressure BioSciences Inc., acquired 14,429 shares of common stock.
- The acquisition was a result of interest paid on convertible preferred stock.
- The price per share was $0.028.
- Following the transaction, Urdea directly owns 47,588 shares of Pressure BioSciences Inc.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing detailing a transaction. It doesn't inherently convey positive or negative sentiment.
Industry Context
This is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the trading activities of company insiders.
Stakeholder Impact
- The transaction may have a minor impact on shareholders due to the increase in the number of outstanding shares, but the effect is likely minimal given the relatively small number of shares involved.
Key Dates
| Date | Description |
|---|---|
| 09/27/2024 | Date of transaction: Michael S Urdea acquired shares of common stock. |
| 09/30/2024 | Date of signature for the Form 4 filing. |
Keywords
Pressure BioSciences Inc, PBIO, Form 4, Michael S Urdea, Director, Stock Acquisition, Convertible Preferred Stock, Interest Payment, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.